Triumeq appears to be safe and well tolerated in patients with MND. It is currently used safely to treat people with HIV, which is a virus known as a retrovirus. Retroviruses are ancient viruses that have left their genetic material in our DNA during the process of human evolution. In some people, this old genetic material may become activated and play a role in the development of MND.
Results from earlier trials of Triumeq indicate that it may have a a positive effect on both clinical measurement and survival of people with ALS (amyotrophic lateral sclerosis), which is the most common form of MND.
However, this was only a small study and the much larger international phase 3 Lighthouse II will determine if Triumeq improves both survival and clinical progression.
Recruitment for Phase 3 of this trial is now complete.
For more information visit clinicaltrials.gov
For outcomes from earlier trials of Triumeq you can read a 2019 publication titled Safety and tolerability of Triumeq in amyotrophic lateral sclerosis: the Lighthouse trial
